Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia
NCT ID: NCT00492037
Last Updated: 2014-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
83 participants
INTERVENTIONAL
2000-01-31
2002-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
NCT00478192
Applying Nutrient Drink Test in Understanding Pathophysiology of CVS
NCT03470181
A Study of TAK-105 in Healthy Adults
NCT04964258
Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
NCT04318847
Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
NCT00691275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM087 oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Plasma Osmolarity \<290 mOsmol/kg H2O
Exclusion Criteria
* Serum sodium increase of ≥8 mEq/L over the baseline day ( Hours 0 to 12)
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parke-Davis
INDUSTRY
Cumberland Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Art Wheeler, MD
Role: STUDY_DIRECTOR
Cumberland Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brussels, , Belgium
Liège, , Belgium
Tournai, , Belgium
Jyväskylä, , Finland
Turku, , Finland
Garches, , France
Limoges, , France
Paris, , France
Bad Nauheim, , Germany
Berlin, , Germany
Dresdan, , Germany
Göttingen, , Germany
München, , Germany
Ferrara, , Italy
Pavia, , Italy
Pisa, , Italy
Verona, , Italy
Delft, , Netherlands
Groningen, , Netherlands
Leiden, , Netherlands
Nijmegen, , Netherlands
Radomsko, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Barcelona, , Spain
Córdoba, , Spain
Madrid, , Spain
Cardiff, , United Kingdom
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1025-023
Identifier Type: -
Identifier Source: secondary_id
087-CL-043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.